Cargando…

Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment

Various molecular mechanisms have been implicated in the progression from hormone-sensitive to castration-resistant prostate cancer (CRPC). Novel targeted agents to treat CRPC have been developed that inhibit either androgen receptor (AR)-mediated signaling (AR antagonists and inhibitors of androgen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aggarwal, Rahul, Ryan, Charles J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2011
Materias:	Academia-Pharma Intersect
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228103/ https://www.ncbi.nlm.nih.gov/pubmed/21339259 http://dx.doi.org/10.1634/theoncologist.2010-0216

Ejemplares similares

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
por: Wander, Seth A, et al.
Publicado: (2022)

Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
por: Scagliotti, Giorgio, et al.
Publicado: (2010)

Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted Therapies
por: Larkin, James M.G., et al.
Publicado: (2010)

Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review
por: Rosen, Lee S., et al.
Publicado: (2010)

Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
por: Thatcher, Nicholas, et al.
Publicado: (2010)

Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2010)

Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction
por: Wang, Tzu-Fei, et al.
Publicado: (2023)

Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents
por: Moxley, Katherine M., et al.
Publicado: (2010)

Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
por: Cameron, David, et al.
Publicado: (2010)

Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
por: Sherrill, Beth, et al.
Publicado: (2010)

Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery
por: Tejpar, Sabine, et al.
Publicado: (2010)

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
por: Garbe, Claus, et al.
Publicado: (2011)

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
por: Ludwig, Heinz, et al.
Publicado: (2010)

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
por: Agarwala, Sanjiv S., et al.
Publicado: (2010)

Effect of Patient Age on Management Decisions in Breast Cancer: Consensus from a National Consultation
por: Leonard, Robert C., et al.
Publicado: (2010)

The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
por: Castellano, Daniel, et al.
Publicado: (2011)

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US
por: Vachhani, Pankit, et al.
Publicado: (2022)

Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases
por: Aapro, Matti, et al.
Publicado: (2010)

Epoetin Alfa Improves Anemia and Anemia-Related, Patient-Reported Outcomes in Patients with Breast Cancer Receiving Myelotoxic Chemotherapy: Results of a European, Multicenter, Randomized, Controlled Trial
por: Pronzato, Paolo, et al.
Publicado: (2010)

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
por: Extra, Jean-Marc, et al.
Publicado: (2010)

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
por: Popat, Sanjay, et al.
Publicado: (2022)

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
por: Boccia, Ralph, et al.
Publicado: (2022)

Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy
por: Baik, Christina S., et al.
Publicado: (2017)

Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents
por: Shah, Ami N., et al.
Publicado: (2020)

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents
por: Cheson, Bruce D., et al.
Publicado: (2017)

Intratumoral Immunotherapy—Update 2019
por: Hamid, Omid, et al.
Publicado: (2019)

What is linking COVID-19 and endothelial dysfunction? Updates on nanomedicine and bioengineering from the 2020 AHA Scientific Sessions
por: Gambardella, Jessica, et al.
Publicado: (2020)

News
Publicado: (2023)

Laughter therapy: A humor-induced hormonal intervention to reduce stress and anxiety
por: Akimbekov, Nuraly S., et al.
Publicado: (2021)

Getting everyone to the table: exploring everyday and everynight work to consider ‘latent social threats’ through interprofessional tabletop simulation
por: Brydges, Ryan, et al.
Publicado: (2021)

Critical design choices in healthcare simulation education: a 4C/ID perspective on design that leads to transfer
por: Frerejean, Jimmy, et al.
Publicado: (2023)

Female excellence in rock climbing likely has an evolutionary origin
por: Carroll, Collin
Publicado: (2021)

High-fat diet-associated cognitive decline: Is zinc finger protein 1 (ZPR1) the molecular connection?
por: Chittilla, Mythri, et al.
Publicado: (2021)

Data-driven resuscitation training using pose estimation
por: Weiss, Kerrin E., et al.
Publicado: (2023)

Measuring cognitively demanding activities in pediatric out-of-hospital cardiac arrest
por: Bahr, Nathan, et al.
Publicado: (2023)

Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
por: Adamo, Vincenzo, et al.
Publicado: (2012)

Castration-resistant prostate cancer: potential targets and therapies
por: Parray, Aijaz, et al.
Publicado: (2012)

Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
por: Amaral, Teresa Maria Santos, et al.
Publicado: (2012)

Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
por: Arshad, Osama Ali, et al.
Publicado: (2017)

Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
por: Han, Harry J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mncb08c1mhem5tjnpdtc0cbiuj